(Q38773323)

6 September 2017

title

Status of vaccine research and development of vaccines for dengue (English)

1 reference

6 September 2017

0 references

2

Anna Durbin

1 reference

6 September 2017

3

Joachim Hombach

1 reference

6 September 2017

Kirsten S Vannice

1

1 reference

6 September 2017

language of work or name

English

0 references

publication date

10 March 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

34

1 reference

6 September 2017

issue

26

1 reference

6 September 2017

page(s)

2934-2938

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

6 September 2017

1 reference

A critical assessment of vector control for dengue prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Health economics of dengue: a systematic literature review and expert panel's assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

The global distribution and burden of dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Dengue: the risk to developed and developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Recent advances in dengue pathogenesis and clinical management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Economic impact of dengue illness in the Americas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Identifying protective dengue vaccines: guide to mastering an empirical process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

A prospective study of dengue infections in Bangkok

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Guidelines for clinical trials of dengue vaccine in endemic areas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Efficacy of a tetravalent dengue vaccine in children in Latin America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

A Candidate Dengue Vaccine Walks a Tightrope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Utility, limitations, and future of non-human primates for dengue research and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Dengue human infection models to advance dengue vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Evaluation of dengue virus strains for human challenge studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

The dengue vaccine pipeline: Implications for the future of dengue control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Next generation dengue vaccines: A review of the preclinical development pipeline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.073

10.1016/J.VACCINE.2015.12.073

7 January 2021

Identifiers

DOI

1 reference

release_nplgkq5djzfgzexvv7hmgif5jy

6 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nplgkq5djzfgzexvv7hmgif5jy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference